INPROSUB SOLUTION

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

PROGESTERONE

Prieinama:

IBSA INSTITUT BIOCHIMIQUE SA

ATC kodas:

G03DA04

INN (Tarptautinis Pavadinimas):

PROGESTERONE

Dozė:

25MG

Vaisto forma:

SOLUTION

Sudėtis:

PROGESTERONE 25MG

Vartojimo būdas:

SUBCUTANEOUS

Vienetai pakuotėje:

100

Recepto tipas:

Prescription

Gydymo sritis:

PROGESTINS

Produkto santrauka:

Active ingredient group (AIG) number: 0106327010; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2021-04-30

Prekės savybės

_INPROSUB™ (progesterone injection) _
_ _
_Page 1 of 33_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
INPROSUB™
Progesterone Injection
Solution, 25 mg / 1.112 mL (22.5 mg / mL) progesterone, subcutaneous
injection
House Standard
Progestin
Institut Biochimique SA (IBSA)
Via del Piano 266
CH-6915 Pambio-Noranco,
Switzerland
Imported by:
Progress Therapeutics Inc.
14-320 Harry Walker Parkway North
Newmarket ON
Canada, L3Y 7B4
Date of Initial Authorization:
June 21, 2021
Submission Control No: 239820
_ _
_INPROSUB™ (progesterone injection) _
_Page 2 of 33_
TABLE OF CONTENTS
TABLE OF CONTENTS
.......................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION ....................................................... 4
1
INDICATIONS ...........................................................................................................
4
1.1
Pediatr
ics.............................................................................................................4
1.2
Ger iatr
ics.............................................................................................................4
2
CONTRAINDICATIONS ...........................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
.............................................................. 5
4
DOSAGE AND ADMINISTRATION .........................................................................
5
4.1
Dosing Considerations
.........................................................................................5
4.2
Recommended Dose and Dosage Adjustment
.......................................................5
4.3
Administration.....................................................................................................5
4.4
Missed Dose
........................................................................................................6
5
OVERDOSAGE ......................................................